Pharma APIs can be categorized into two primary types chemical APIs and biological APIs. Chemical APIs are typically synthesized through chemical processes in laboratories. These include small-molecule drugs, which are often small organic compounds designed for specific therapeutic effects. On the other hand, biological APIs, commonly referred to as biotech drugs, are derived from living organisms. They encompass a range of products such as monoclonal antibodies, peptides, and vaccines, which generally offer targeted therapies for complex diseases.
With increasing global awareness of environmental protection, the pharmaceutical industry is actively exploring green chemistry practices to reduce production-related pollution. Eco-friendly pharma intermediates are a significant result of this trend. By using low-toxicity, low-emission intermediates and optimizing synthetic routes, waste and emissions in antibiotic production are effectively controlled. For instance, replacing traditional chemical catalysts with biocatalysts can significantly reduce the use of harmful solvents, while also improving reaction selectivity and efficiency.
Moreover, PQQ encourages a culture of transparency and accountability. In an age where businesses are increasingly held accountable for their environmental impact and social responsibility, suppliers that complete a PQQ are often required to demonstrate their commitment to sustainability and ethical practices. This aspect of PQQ not only governs the selection of suppliers but also inspires innovation in sustainable practices, benefitting the environment and enhancing brand reputation.